Cronos Group (CRON) Q3 2024 earnings summary

Executive summary

• Achieved record consolidated net revenue of $34.3 million in Q3 2024, up 38% year-over-year, driven by strong flower and extract sales in Canada, Israel, and international markets.

• Spinach became the top cannabis brand in Canada, leading in edibles and flower, and expanding its product portfolio.

• Expanded Growco facility with a $51 million credit facility, consolidating Growco's results and gaining majority board control.

• Strong balance sheet with $862 million in cash and cash equivalents, positioning for future growth and market entry.

Financial highlights

• Net revenue excluding Growco was $30 million, up 21% year-over-year; Growco contributed $4.3 million.

• Gross profit was $3.6 million (11% margin); adjusted gross profit was $10.7 million (31% margin) after inventory step-up adjustment.

• Adjusted EBITDA was negative $6 million, a $9.2 million improvement from the prior year.

• Positive cash flow from operations of $11.6 million and free cash flow of $5 million, both significant improvements year-over-year.

Outlook and guidance

• Tracking toward the high end of $5–$10 million in OpEx savings for 2024 on a standalone basis, though Growco consolidation will offset some savings next year.

• Expect increased CapEx levels due to Growco phase two expansion, with total CapEx for the project around $51 million, to be completed by mid-year.

• Anticipate continued demand growth in Canada, Israel, and Europe, with plans to expand international presence.